Biomarkers PRIORITY AREA
Why Are Biomarkers a Priority?
The identification, development and use of biomarkers to diagnose and track Parkinson's disease would mean better disease management for patients. More so, biomarkers could measure a drug's effect on Parkinson's disease, improving and speeding clinical development of disease-modifying therapies. Biomarkers can inform critical "go/no-go" decisions within companies and can ensure that clinical trials provide clearer and more definitive results. No definitive biomarker of Parkinson's disease has yet been identified, but the Foundation devotes significant resources to the effort to do so.
Our Investment in Biomarkers Research
The Michael J. Fox Foundation has been a field leader in Parkinson's disease biomarker discovery, optimization and verification through multiple funding and strategic initiatives. These include supporting the development of biological assays for detecting disease-relevant proteins in blood and CSF and testing brain imaging methods (e.g., transcranial sonography, MRI and PET) as possible biomarkers for Parkinson's disease. Currently, The Foundation is sponsoring the Parkinson's Progression Marker Initiative (PPMI), a five-year landmark clinical study aiming to identify biomarkers of Parkinson's disease progression and the Fox Investigation for New Discovery of Biomarkers (BioFIND), a two-year clinical study aiming to collect clinical data and biospecimen for biomarker discovery.
Accelerate Your Research
Access Research Tools
Select from pre-clinical models, reagents, research data and more.
Sign-up for Emails
Receive regular updates on funding opportunities and other resources.